Please assess the completion status of the following clinical trial:

Trial Title: Lobectomy and Mediastinal Radiochemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer Responding to Induction Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of non-small cell carcinoma of the lung~* Initially stage III NSCLC~* Pathologically proven N2 or N3 disease~* Any response to induction chemotherapy (whatever the regimen administered)~* Disease still not fully resectable (because of extensive mediastinal N disease) and not suitable for radical radiotherapy (single field) after induction chemotherapy~* Lobectomy possible for the treatment of T disease~* Availability for participating in the detailed follow-up of the protocol~* Informed consent~Exclusion Criteria:~* Prior treatment with radiotherapy or surgery~* Karnofsky PS \< 60~* Functional or anatomical contra-indication to mediastinal radiotherapy~* Functional or anatomical contra-indication to surgical lobectomy~* A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)~* Malignant pleural or pericardial effusion~* Neutrophils \< 2,000/mm³~* Platelet cells \< 100,000/mm3~* Serum bilirubin \> 1.5 mg/100 ml~* Serum creatinine \> 1.5 mg/100 ml and/or creatinine clearance \< 60 ml/min~* Recent myocardial infarction (less than 3 months prior to date of diagnosis)~* Congestive cardiac failure or cardiac arrhythmia requiring medical treatment~* Uncontrolled infectious disease~* Hearing loss~* Symptomatic polyneuropathy~* Serious medical or psychological factors which may prevent adherence to the treatment schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Lobectomy followed by mediastinal concomitant chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).